BR0312003A - Metastable pharmaceutical compositions for transdermal delivery and their uses - Google Patents

Metastable pharmaceutical compositions for transdermal delivery and their uses

Info

Publication number
BR0312003A
BR0312003A BR0312003-1A BR0312003A BR0312003A BR 0312003 A BR0312003 A BR 0312003A BR 0312003 A BR0312003 A BR 0312003A BR 0312003 A BR0312003 A BR 0312003A
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
transdermal delivery
metastable
physiologically active
volatile solvent
Prior art date
Application number
BR0312003-1A
Other languages
Portuguese (pt)
Inventor
Nina Frances Wilkins
Kathryn Traci-Jane Klose
Timothy Matthias Morgan
Barry Leonard Reed
Barrie Charles Finnin
Original Assignee
Acrux Dds Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acrux Dds Pty Ltd filed Critical Acrux Dds Pty Ltd
Publication of BR0312003A publication Critical patent/BR0312003A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Abstract

"COMPOSIçõES FARMACêUTICAS METAESTáVEIS PARA DISTRIBUIçãO TRANSDéRMICA E SEUS USOS". A presente invenção proporciona uma composição farmacêutica para distribuição transdérmica compreendendo: um ou mais agentes fisiologicamente ativos; e um solvente volátil farmaceuticamente aceitável; onde o agente fisiologicamente ativo forma um depósito metaestável mediante evaporação do solvente volátil."Metastable pharmaceutical compositions for transdermal distribution and their uses". The present invention provides a pharmaceutical composition for transdermal delivery comprising: one or more physiologically active agents; and a pharmaceutically acceptable volatile solvent; where the physiologically active agent forms a metastable deposit upon evaporation of the volatile solvent.

BR0312003-1A 2002-06-25 2003-06-24 Metastable pharmaceutical compositions for transdermal delivery and their uses BR0312003A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPS3173A AUPS317302A0 (en) 2002-06-25 2002-06-25 Metastable pharmaceutical compositions
PCT/AU2003/000785 WO2004000361A1 (en) 2002-06-25 2003-06-24 Metastable pharmaceutical compositions

Publications (1)

Publication Number Publication Date
BR0312003A true BR0312003A (en) 2005-03-22

Family

ID=3836732

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0312003-1A BR0312003A (en) 2002-06-25 2003-06-24 Metastable pharmaceutical compositions for transdermal delivery and their uses

Country Status (9)

Country Link
EP (1) EP1531867A4 (en)
JP (2) JP2005534670A (en)
KR (1) KR20050120726A (en)
AU (1) AUPS317302A0 (en)
BR (1) BR0312003A (en)
CA (1) CA2490057A1 (en)
EA (1) EA012648B1 (en)
NZ (1) NZ537436A (en)
WO (1) WO2004000361A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2830519A1 (en) * 2011-03-22 2012-09-27 The Population Council, Inc. Myelin regeneration with androgens

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0794378B2 (en) * 1989-08-18 1995-10-11 久光製薬株式会社 Aerosol
JPH0383924A (en) * 1989-08-28 1991-04-09 Kanebo Ltd Composition for percutaneous administration
JP2974081B2 (en) * 1990-07-26 1999-11-08 小池化学株式会社 Aerosol composition for human body
DK0553298T3 (en) * 1990-10-18 1995-04-18 Minnesota Mining & Mfg Aerosol formulation comprising beclomethasone 17,21 dipropionate
CA2101496A1 (en) * 1992-07-31 1994-02-01 Masao Kobayashi Base for transdermal administration
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
DE19616539A1 (en) * 1996-04-25 1997-11-06 Luitpold Pharma Gmbh Alcoholic solutions containing acetylsalicylic acid for percutaneous use, their use for antithrombotic therapy and medicines
US5968919A (en) * 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin
RO121628B1 (en) * 1999-02-05 2008-01-30 Cipla Limited Sprayable topical medicinal composition, dispenser containing the same, process for manufacturing the dispenser and use of the mentioned composition
US6368618B1 (en) * 1999-07-01 2002-04-09 The University Of Georgia Research Foundation, Inc. Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs
EP2283865A1 (en) * 2000-08-30 2011-02-16 Unimed Pharmaceuticals, LLC Method of increasing testosterone and related steroid concentrations in women
MXPA03001859A (en) * 2000-08-30 2004-05-21 Unimed Pharmaceuticals Inc Method of increasing testosterone and related steroid concentrations in women.

Also Published As

Publication number Publication date
WO2004000361A1 (en) 2003-12-31
KR20050120726A (en) 2005-12-23
EP1531867A1 (en) 2005-05-25
CA2490057A1 (en) 2003-12-31
EA012648B1 (en) 2009-12-30
EP1531867A4 (en) 2011-03-23
JP2010248250A (en) 2010-11-04
AUPS317302A0 (en) 2002-07-18
EA200500083A1 (en) 2005-08-25
JP2005534670A (en) 2005-11-17
NZ537436A (en) 2007-01-26

Similar Documents

Publication Publication Date Title
ES2156028T3 (en) Compositions containing tetrahydrolipstatin
BR0100949A (en) Inhibition of oxidative degradation of pharmaceutical formulations
BRPI0513300A (en) oral dosage form, protected from abuse, containing (1r, 2r) -3- (3-dimethylamino-1-ethyl-2-propyl) -phenol
BRPI0415007A (en) method for treating, preventing, modifying or administering pain and pharmaceutical composition
BR9808888A (en) Dosage forms and method of improving male erectile dysfunction
ATE293995T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS THAT PROMOTE DRUG ABSORPTION
BR0207930A (en) Masked flavor liquid pharmaceutical compositions
BR0108584A (en) Formulations containing an anticholinergic drug for the treatment of chronic obstructive bronchopneumopathy
BRPI0113331B8 (en) phenylalanine derivatives or their pharmaceutically acceptable salts, alpha 4 integrin antagonist, therapeutic agent or preventive agent for inflammatory diseases, and pharmaceutical composition
BR0115965A (en) Pharmaceutical compositions for oral release of pharmacologically active agents
NO20062504L (en) Compositions and dosage forms for improved absorption
ATE387430T1 (en) COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE INGREDIENTS
BR0312007A (en) Transcutaneous administration rate control using amorphous pharmaceutical compositions
BRPI0415971A (en) method for treating, preventing or controlling macular degeneration, and pharmaceutical composition
BRPI0412211A (en) controlled release compositions
BRPI0411165A (en) pharmaceutical composition, dosage unit form and methods for preparing its use
ATE260647T1 (en) MECHANICALLY STABLE PHARMACEUTICAL DOSAGE FORMS CONTAINING LIQUID OR SEMI-SOLIDS SURFACE-ACTIVE SUBSTANCES
BRPI0408655A (en) formulations comprising an active agent and cocoa powder and their use
AR044200A1 (en) COMPOSITION OF FONDAPARINUX SODICO DE HIGH PURITY, A PROCEDURE FOR THE PREPARATION OF THIS COMPOSITION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT AS AN ACTIVE PRINCIPLE
ATE549015T1 (en) PHARMACEUTICAL FORMULATION CONTAINING ACTIVE INGREDIENTS WITH COATING
ATE375789T1 (en) ORAL DELIVERY SYSTEM CONTAINING AN ANTIBACTERIAL AND AN ANTI-INFLAMMATORY AGENT
DK1345595T3 (en) Ion strength-independent pharmaceutical formulation with depot release
MX9400801A (en) TETRAHIDROPIRIDINNA O-SUBSTITUTED OXYM COLLERGIC AGENTS STABILIZED WITH STARCH.
AR032642A1 (en) CHEMOTHERAPICAL COMPOSITIONS OF PACLITAXEL IN MICROEMULSION WITH GREATER ORAL BIODISPONIBILITY.
BRPI0412364A (en) solid pharmaceutical composition comprising amisulpride

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2157 DE 08/05/2012.